• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

克罗恩病患者的风险分层:临床决策制定及其对长期结局影响的回顾性分析

Risk Stratification of Patients with Crohn's Disease: A Retrospective Analysis of Clinical Decision Making and Its Impact on Long-Term Outcome.

作者信息

Mosli Mahmoud, Sabbahi Hanadi, Alyousef Hind, Abdulhaq Mada, Hadadi Afnan, Aljahdali Emad, Jawa Hani, Bazarah Salem, Qari Yousif

机构信息

Department of Medicine, King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia.

出版信息

Dig Dis. 2018;36(1):49-55. doi: 10.1159/000477613. Epub 2017 Jun 28.

DOI:10.1159/000477613
PMID:28654928
Abstract

BACKGROUND AND AIMS

Complications such as need for bowel resections and hospitalization due to Crohn's disease (CD) occur when disease activity persists due to ineffective therapy. Certain "high-risk" features require an early introduction of anti-tumor necrosis factor-α therapy to prevent such complications. We aim to evaluate the prevalence of "high-risk" features among a cohort of patients with CD and examine the association between discordance of early therapy with baseline risk stratification and disease outcome.

PATIENTS AND METHODS

All adult patients with CD were retrospectively identified and their medical records were reviewed. Clinical, endoscopic, laboratory, and radiological data were collected. Patients were divided into "low" and "high" risk groups according to the presence or absence of penetrating disease, perianal involvement, foregut involvement, extensive disease seen on endoscopy or cross-sectional imaging, young age at the time of diagnosis (<40), persistent cigarette smoking and frequent early requirements for corticosteroid therapy. Initial treatment selection and treatment approach ("step-up" vs. "accelerated step-up" vs. "top-down") within 6 months of diagnosis were recorded. Rates of CD-related bowel resections and hospitalization within 5 years of diagnosis were calculated. Logistic regression analysis was used to examine the association between "discordance" of early treatment selections and risk stratification categories with outcomes.

RESULTS

Eighty-five CD patients were included. The median age and duration of disease were 25 (interquartile range [IQR] 19-32) and 5 (IQR 4-6) years, respectively. Sixty five percent were females and 66% were native Saudis. Smoking was reported in 12% of patients and perianal disease in 18%. "High-risk" features were identified in 43 (51%) patients, of which only 6 (14%) were treated with "top-down" therapy and 7 (16%) with "accelerated step-up" care. The risk of requiring a bowel resection, and hospitalization was higher for "high-risk" patients compared to "low-risk" patients (risk ratio [RR] 13.67, 95% CI 1.88-99.41; p = 0.003, and RR 1.86, 95% CI 0.03-0.43; p = 0.0312, respectively). "Discordance" occurred in 34% of cases. Bowel resection was required in 15/85 (18%) patients and 32/85 (38%) required at least one hospitalization within 5 years of diagnosis. Logistic regression analysis identified a statistically significant association between "discordance" and need for bowel resections (OR 6.50, 95% CI 1.59-26.27, p = 0.009), and hospitalizations (OR 3.01, 95% CI 1.08-8.39, p = 0.035) within 5 years of diagnosis.

CONCLUSIONS

"Discordance" between patient risk-profile and treatment selection early in the course of CD has a significant impact on disease outcome, specifically need for bowel resection and hospitalization, which are more likely to occur in the presence of "high-risk" features. Early identification of "high-risk" features could help prevent long-term complications.

摘要

背景与目的

当因治疗无效导致疾病活动持续存在时,会出现诸如因克罗恩病(CD)而需要进行肠道切除和住院治疗等并发症。某些“高危”特征需要尽早引入抗肿瘤坏死因子-α治疗以预防此类并发症。我们旨在评估一组CD患者中“高危”特征的患病率,并研究早期治疗与基线风险分层不一致与疾病结局之间的关联。

患者与方法

对所有成年CD患者进行回顾性识别并查阅其病历。收集临床、内镜、实验室和放射学数据。根据是否存在穿透性疾病、肛周受累、前肠受累、内镜或横断面成像显示的广泛性疾病、诊断时年龄较轻(<40岁)、持续吸烟以及频繁早期需要使用皮质类固醇治疗,将患者分为“低”和“高”风险组。记录诊断后6个月内的初始治疗选择和治疗方法(“逐步升级”与“加速逐步升级”与“自上而下”)。计算诊断后5年内与CD相关的肠道切除率和住院率。采用逻辑回归分析来研究早期治疗选择与风险分层类别之间的“不一致”与结局之间的关联。

结果

纳入了85例CD患者。疾病的中位年龄和病程分别为25岁(四分位间距[IQR]19 - 32)和5年(IQR 4 - 6)。65%为女性,66%为沙特本地人。12%的患者有吸烟史,18%有肛周疾病。43例(51%)患者具有“高危”特征,其中仅6例(14%)接受了“自上而下”治疗,7例(16%)接受了“加速逐步升级”治疗。与“低风险”患者相比,“高风险”患者需要进行肠道切除和住院的风险更高(风险比[RR]13.67,95%置信区间[CI]1.88 - 99.41;p = 0.003,以及RR 1.86,95% CI 0.03 - 0.43;p = 0.0312)。34%的病例出现了“不一致”。15/85(18%)的患者需要进行肠道切除,32/85(38%)的患者在诊断后5年内至少需要住院一次。逻辑回归分析确定“不一致”与诊断后5年内需要进行肠道切除(比值比[OR]6.50,95% CI 1.59 - 26.27,p = 0.009)以及住院(OR 3.01,95% CI 1.08 - 8.39,p = 0.035)之间存在统计学上显著的关联。

结论

CD病程早期患者风险特征与治疗选择之间的“不一致”对疾病结局有显著影响,特别是对肠道切除和住院的需求,在存在"高危"特征时更有可能发生。早期识别“高危”特征有助于预防长期并发症。

相似文献

1
Risk Stratification of Patients with Crohn's Disease: A Retrospective Analysis of Clinical Decision Making and Its Impact on Long-Term Outcome.克罗恩病患者的风险分层:临床决策制定及其对长期结局影响的回顾性分析
Dig Dis. 2018;36(1):49-55. doi: 10.1159/000477613. Epub 2017 Jun 28.
2
Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes?溃疡性结肠炎患者的基线风险评估:初始治疗选择是否会影响预后?
Eur J Gastroenterol Hepatol. 2019 Jan;31(1):80-85. doi: 10.1097/MEG.0000000000001249.
3
Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study.硫唑嘌呤或抗 TNF 药物起始使用时间与克罗恩病患者腹部大手术风险相关:一项回顾性队列研究
J Crohns Colitis. 2016 Jan;10(1):55-60. doi: 10.1093/ecco-jcc/jjv187. Epub 2015 Oct 31.
4
Prevalence and predictors of hospitalization in Crohn's disease in a prospective population-based inception cohort from 2000-2012.2000年至2012年基于前瞻性人群的初始队列中克罗恩病住院情况的患病率及预测因素
World J Gastroenterol. 2015 Jun 21;21(23):7272-80. doi: 10.3748/wjg.v21.i23.7272.
5
A risk score system to timely manage treatment in Crohn's disease: a cohort study.一种用于克罗恩病治疗及时管理的风险评分系统:一项队列研究。
BMC Gastroenterol. 2018 Nov 6;18(1):164. doi: 10.1186/s12876-018-0889-5.
6
Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres.抗 TNF 治疗期间住院率的下降趋势与开始抗 TNF 治疗的时间相关:来自两个转诊中心的结果。
Dig Liver Dis. 2014 Nov;46(11):985-90. doi: 10.1016/j.dld.2014.07.168. Epub 2014 Aug 22.
7
A comprehensive review and update on Crohn's disease.克罗恩病的全面综述与更新
Dis Mon. 2018 Feb;64(2):20-57. doi: 10.1016/j.disamonth.2017.07.001. Epub 2017 Aug 18.
8
The long-term outcome of anti-TNF alpha therapy in perianal Crohn's disease.抗肿瘤坏死因子α疗法治疗肛周克罗恩病的长期疗效
Tech Coloproctol. 2017 Feb;21(2):119-124. doi: 10.1007/s10151-016-1578-4. Epub 2017 Jan 9.
9
Clinical predictors of thiopurine-related adverse events in Crohn's disease.克罗恩病中硫唑嘌呤相关不良事件的临床预测因素
World J Gastroenterol. 2015 Jul 7;21(25):7795-804. doi: 10.3748/wjg.v21.i25.7795.
10
Risk factors for diagnostic delay in Crohn's disease and their impact on long-term complications: how do they differ in a tuberculosis endemic region?克罗恩病诊断延迟的危险因素及其对长期并发症的影响:在结核病流行地区有何不同?
Aliment Pharmacol Ther. 2018 May;47(10):1367-1374. doi: 10.1111/apt.14617. Epub 2018 Mar 24.

引用本文的文献

1
Patient-Related Factors Associated With Long-Term Outcomes After Successful Endoscopic Balloon Dilation For Crohn's Disease-Associated Ileo-Colic Strictures: A Systematic Review and Meta-analysis.克罗恩病相关性回结肠狭窄成功内镜下球囊扩张术后长期预后的患者相关因素:一项系统评价和荟萃分析
Crohns Colitis 360. 2024 Aug 4;6(3):otae041. doi: 10.1093/crocol/otae041. eCollection 2024 Jul.
2
Selecting first-line advanced therapy for ulcerative colitis: A clinical application of personalized medicine.溃疡性结肠炎一线高级治疗药物的选择:个性化医学的临床应用。
Saudi J Gastroenterol. 2024 May 1;30(3):126-137. doi: 10.4103/sjg.sjg_427_23. Epub 2024 Apr 10.
3
A Retrospective Observational Study of Patterns of Biologic Drug Change in Inflammatory Bowel Disease.
炎症性肠病生物药物变化模式的回顾性观察研究
Inflamm Intest Dis. 2024 Mar 12;9(1):71-84. doi: 10.1159/000538250. eCollection 2024 Jan-Dec.
4
Inflammatory Bowel Disease: Clinical Diagnosis and Pharmaceutical Management.炎症性肠病:临床诊断与药物治疗
Med Res Arch. 2023 Jan;11(1). doi: 10.18103/mra.v11i1.3135. Epub 2023 Jan 31.
5
Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview.炎症性肠病:临床诊断与外科治疗概述。
Medicina (Kaunas). 2022 Apr 21;58(5):567. doi: 10.3390/medicina58050567.
6
Retrospective Study of Surgical Outcomes in 60 Patients with Crohn Disease from a Single Center in Poland.波兰单中心 60 例克罗恩病患者的手术治疗结局回顾性研究。
Med Sci Monit. 2022 Jan 12;28:e934463. doi: 10.12659/MSM.934463.
7
Prognostic biomarkers to identify patients likely to develop severe Crohn's disease: a systematic review.预测生物标志物识别可能发展为严重克罗恩病的患者:系统评价。
Health Technol Assess. 2021 Jul;25(45):1-66. doi: 10.3310/hta25450.
8
Clinical characteristics, natural history, and outcomes of Crohn's-related intra-abdominal collections.克罗恩病相关腹腔内脓肿的临床特征、自然史和转归。
Saudi J Gastroenterol. 2021 Mar-Apr;27(2):79-84. doi: 10.4103/sjg.SJG_89_20.
9
Personalising medicine in inflammatory bowel disease-current and future perspectives.炎症性肠病的个性化医疗——现状与未来展望
Transl Pediatr. 2019 Jan;8(1):56-69. doi: 10.21037/tp.2018.12.03.